Cefazolin

Generic Name: Cefazolin

Drug Type: Small Molecule

Chemical Formula: C_₁₄H_₁₄N_₈O_₄S_₃

CAS Number: 25953-19-9

Unique Ingredient Identifier: IHS69L0Y4T

Background: A semisynthetic cephalosporin analog with broad-spectrum antibiotic action due to inhibition of bacterial cell wall synthesis. It attains high serum levels and is excreted quickly via the urine.

Indication: Mainly used to treat bacterial infections of the skin. It can also be used to treat moderately severe bacterial infections involving the lung, bone, joint, stomach, blood, heart valve, and urinary tract. It is clinically effective against infections caused by staphylococci and streptococci species of Gram positive bacteria. May be used for surgical prophylaxis; if required metronidazole may be added to cover B. fragilis.

Associated Conditions: Bacterial Septicemia caused by susceptible Bacterial Infections, Biliary tract infection bacterial caused by susceptible Bacterial Infections, Bone and Joint Infections caused by susceptible Bacterial Infections, Catheter-related Bloodstream Infection (CRBSI) NOS, Community Acquired Pneumonia (CAP), Endocarditis caused by susceptible Bacterial Infections, Genital infection caused by susceptible Bacterial Infections, Osteoarticular Infections, Postoperative Infections, Respiratory Tract Infection Bacterial caused by susceptible Bacterial Infections, Skin and Soft Tissue Infections (SSTIs), Skin and Subcutaneous Tissue Infection caused by susceptible Bacterial Infections, Susceptible infections, Urinary Tract Infection caused by susceptible Bacterial Infections, Perioperative infection, Susceptible Bacterial Infections

Associated Therapies: Antibiotic pre-surgical prophylaxis

Clinical Trials

Antibiotics During Intrauterine Balloon Tamponade Placement

Phase 4

Terminated

Conditions: Obstetric Complication
Postpartum Hemorrhage
Postpartum Endometritis

Interventions: Drug: CeFAZolin 1000 MG
Drug: Clindamycin 900 MG in 6 ML Injection

First Posted Date: 2018-03-27

Last Posted Date: 2021-10-07

Lead Sponsor: Cedars-Sinai Medical Center

Target Recruit Count: 11

Registration Number: NCT03478163

Locations: 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States

The Effectiveness of Vancomycin in Comarison With Cefazolin in Prevention of SSI After Craniotomy

Phase 1

Conditions: Elective Craniotomy-candidated Patients

Interventions: Drug: Vancomycin
Drug: Cefazolin

First Posted Date: 2018-03-15

Last Posted Date: 2018-03-15

Lead Sponsor: Isfahan University of Medical Sciences

Target Recruit Count: 126

Registration Number: NCT03466645

Locations: 🇮🇷
Isfahan university of medical science., Isfahan, Iran, Islamic Republic of

Preoperative Antibiotics for Carpal Tunnel Release Surgery

Phase 4

Completed

Conditions: Carpal Tunnel Syndrome

Interventions: Drug: Cefazolin
Drug: Saline Solution
Drug: Vancomycin

First Posted Date: 2018-02-14

Last Posted Date: 2021-11-10

Lead Sponsor: WellSpan Health

Target Recruit Count: 184

Registration Number: NCT03432858

Locations: 🇺🇸
WellSpan Surgery and Rehab Hospital, York, Pennsylvania, United States

Prevention of Infections in Cardiac Surgery (PICS) Prevena Study

Phase 4

Completed

Conditions: Surgical Site Infections

Interventions: Device: Prevena
Other: standard wound dressing
Drug: Cefazolin
Drug: Vancomycin

First Posted Date: 2018-01-18

Last Posted Date: 2025-02-28

Lead Sponsor: Population Health Research Institute

Target Recruit Count: 4107

Registration Number: NCT03402945

Locations: 🇨🇦
Hamilton General Hospital, Hamilton, Ontario, Canada
🇨🇦
London Health Sciences Centre & Lawson Health Research Institute, London, Ontario, Canada

Antibiotic Prophylaxis in Patients Undergoing Elective TKA- Multi-center Trial

Phase 4

Active, not recruiting

Conditions: Arthropathy of Knee
Antibiotic Prophylaxis

Interventions: Drug: Cefazolin

First Posted Date: 2017-09-14

Last Posted Date: 2025-04-11

Lead Sponsor: Duke University

Target Recruit Count: 8000

Registration Number: NCT03283878

Locations: 🇺🇸
University of California, San Francisco, San Francisco, California, United States
🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸
University of Maryland St. Joseph Medical Center & Orthopedic Associates, Towson, Maryland, United States

and more 11 locations

Antibiotics Usage in Pediatric Orthopaedic Percutaneous Surgery (APOPS)

Phase 4

Completed

Conditions: Supracondylar Humerus Fracture
Post Operative Wound Infection

Interventions: Drug: Saline
Drug: Cefazolin
Drug: Clindamycin

First Posted Date: 2017-08-25

Last Posted Date: 2024-08-09

Lead Sponsor: Sumit Gupta

Target Recruit Count: 160

Registration Number: NCT03261830

Locations: 🇺🇸
University of Missouri Health System, Columbia, Missouri, United States

Non-inferiority Trial Comparing Cloxacillin vs Cefazolin in Methicillin-susceptible Staphylococcus Aureus Bacteremia

Not Applicable

Active, not recruiting

Conditions: Bacteremia Due to Methicillin Susceptible Staphylococcus Aureus

Interventions: Drug: Cloxacillin
Drug: Cefazolin

First Posted Date: 2017-08-14

Last Posted Date: 2023-12-15

Lead Sponsor: Assistance Publique - Hôpitaux de Paris

Target Recruit Count: 315

Registration Number: NCT03248063

Locations: 🇫🇷
François-Xavier Lescure, Paris, France

Safety of 1 g and 2 g of Cefazolin in Pediatric Subjects

Phase 4

Terminated

Conditions: Postoperative Infection

Interventions: Drug: Cefazolin 1 g Infusion
Drug: Cefazolin 2 g Infusion

First Posted Date: 2017-07-27

Last Posted Date: 2020-07-13

Lead Sponsor: B. Braun Medical Inc.

Target Recruit Count: 61

Registration Number: NCT03231228

Locations: 🇺🇸
Arkansas Children's Research Institute, Little Rock, Arkansas, United States
🇺🇸
University of Missouri Health Care System, Columbia, Missouri, United States
🇺🇸
Children's Medical Center Dallas, Dallas, Texas, United States

and more 2 locations

Bacterial Biofilms in Reconstructive Breast Prostheses Following Mastectomy

Phase 1

Completed

Conditions: Mammoplasty
Breast Implant Infection

Interventions: Other: Normal saline
Procedure: Skin biopsy
Drug: Cefazolin
Procedure: Bilateral skin- or nipple-sparing mastectomies
Device: Breast implant
Device: Tissue expander
Procedure: Autologous flap
Other: Acellular dermal matrix sling
Drug: Gentamicin
Drug: Bacitracin

First Posted Date: 2017-07-11

Last Posted Date: 2019-02-08

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 19

Registration Number: NCT03213249

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

Skeletal Muscle and Adipose Tissue Study

Phase 4

Completed

Conditions: Idiopathic Scoliosis

Interventions: Drug: Continuous Cefazolin drip
Drug: Bolus dose of Cefazolin
Device: Paraspinal muscle microdialysis catheters
Device: Subcutaneous microdialysis catheters

First Posted Date: 2017-06-19

Last Posted Date: 2023-07-11

Lead Sponsor: University of Florida

Target Recruit Count: 12

Registration Number: NCT03190668

Locations: 🇺🇸
University of Florida, Gainesville, Florida, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy